Drug Database
IN

insulin (Monotard MC / Novolin L / Human Monotard)

✓ Approved

Novo Nordisk A/S · INSR · 重组蛋白

什么是 insulin?

insulin 是一种重组蛋白,由Novo Nordisk A/S研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intramuscular (IM) Injection、Subcutaneous Injection。

药物档案

商品名Monotard MC, Novolin L, Human Monotard
公司Novo Nordisk A/S
药物类别重组蛋白, 多肽类
分子靶点INSR
给药途径Injectable (Others), Intramuscular (IM) Injection, Subcutaneous Injection
状态Approved

作用机制

分子靶点

insulin 作用于 1 个分子靶点:

INSRinsulin receptor (CD220, HHF5)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

insulin 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 1 diabetes mellitus✓ Approved
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedHaematologica2026-11-19

Outcomes associated with CD3xCD20 bispecific antibody therapies in relapsed/refractory transformed indolent lymphoma.

Stephan Pierre P, Chohan Karan L KL, Redd Robert A RA, Dixon Wendy W et al.

Transformed indolent non-Hodgkin lymphoma (tiNHL) has historically been associated with poor outcomes, particularly for patients with relapsed or refractory (R/R) disease. Although chimeric antigen receptor (CAR) T-cell therapy has improved prognosis, many patients lack access or experience relapse following treatment, highlighting the need for additional therapeutic strategies. CD3×CD20 bispecific antibodies (BsAbs) are active in R/R large B-cell lymphoma (LBCL), though data in tiNHL are limited. Here, we report the efficacy and safety of epcoritamab and glofitamab in patients with R/R tiNHL (N = 74) compared with those of patients with R/R de novo diffuse LBCL (DLBCL; N = 166) from 9 academic centers in the Collaborative US Bispecifics Consortium (CUBIC). With a median follow-up of 11.5 months, best overall response rate (ORR) and complete response rate (CRR) were comparable in tiNHL (50%/31%) vs de novo DLBCL (51%/34%). 12-month progression-free survival was 25% (95% confidence interval [CI], 15-39) for tiNHL vs 34% (95% CI, 27-43) for de novo DLBCL (HR, 1.15 [95% CI, 0.83-1.61]) and 12-month overall survival was 38% (95% CI, 26-55) for tiNHL vs 47% (95% CI, 39-56) for de novo DLBCL (HR, 1.08 [95% CI, 0.73-1.60]). No differences in toxicity were observed. Similar findings were found via a 1:1 propensity score matching statistical approach. In conclusion, our study revealed comparable efficacy and toxicity of BsAbs for patients with R/R tiNHL vs patients with R/R de novo DLBCL, supporting their use in this patient population.

PMID 43053709
阅读全文 →
PubMedJournal of the American Chemical Society2026-11-19

De Novo Design of Catalytically Active Salen-Binding Proteins.

Bakanas Ian I, Horst Maggie M, Ouchida Stephanie S, Jung Sungwon S et al.

De novo design of catalytic metalloproteins has the potential to generate enzymes that combine the efficiency of natural proteins with the reactivity of synthetic organometallic catalysts. Here, we develop a computational strategy to design enzymes with novel tertiary structures that bind metal salen complexes, classic small-molecule catalysts not found in biology. Six proteins were designed and screened for function; five of six express well, bind a Co-salen cofactor, and catalyze a transition metal hydrogen atom transfer (MHAT)-mediated deallylation reaction, representing the first de novo proteins to catalyze this class of transformation. The spectroscopic properties and crystal structure of the most active sequence were in excellent agreement with the design, and the holoprotein retained its structure and activity over a broad range of pH (2-12), temperatures up to 95 °C, and aqueous/organic solvent mixtures. We suggest that the combinatorial space provided by metal ion identity, ligand substitution, and active site structure can be used to generate artificial metalloenzymes that catalyze many chemical transformations.

PMID 43053445
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-11-19

Insulin Secretion Modelling to Characterize Post-Bariatric Hypoglycaemia After Roux-en-Y Gastric Bypass.

Mohammadi-Asl E E, El Fathi A A, Pei L L, Saeed H H et al.

Roux-en-Y Gastric Bypass (RYGB) is an effective treatment for obesity and Type 2 diabetes. Some individuals develop postprandial hypoglycaemia, termed post-bariatric hypoglycaemia (PBH). PBH is associated with marked postprandial increases in incretin and insulin levels. This study investigates how insulin secretion differs between post-RYGB patients with and without hypoglycaemia by identifying key secretion parameters. Insulin secretion was modelled using plasma glucose, insulin and C-peptide concentration data obtained from mixed meal tolerance test in three cohorts: healthy individuals without a history of upper gastrointestinal surgery (controls, n = 11), post-RYGB individuals without hypoglycaemia (RYGB-non-hypo, n = 18) and post-RYGB individuals with hypoglycaemia (RYGB-PBH, n = 20). Meal-driven insulin secretion differed across groups (p = 0.008) and was significantly higher in RYGB-PBH than controls (0.23 vs. 0.14 pmol/mg, p = 0.006), but not in RYGB-non-hypo (0.22, p = 0.071). Glucose-driven insulin secretion decreased in RYGB-non-hypo (0.04 vs. 0.07 pmol/kg/min per mg/dL, p = 0.005) but did not differ from controls in RYGB-PBH (0.08, p = 0.948), differing significantly between the two post-RYGB groups (p < 0.001). Meal absorption was significantly faster in both post-RYGB groups (9.08 and 8.44 vs. 11.48 min, both p < 0.001). Models fit plasma insulin and C-peptide well (mean joint nRMSE: 0.60-0.92 across groups). Parameters were estimated with good precision (CV < 100%). Insulin secretion dynamics differ between post-RYGB patients with and without hypoglycaemia. Both groups showed faster meal absorption and a shift towards higher meal-driven secretion, significant only in RYGB-PBH, but only those without hypoglycaemia showed a reduction in glucose-driven secretion. This PBH model can support in silico development of glucagon-based interventions.

PMID 43053530
阅读全文 →
PubMedSmall (Weinheim an der Bergstrasse, Germany)2026-11-19

Synergistic Molecular Interfacial Bridging and Solvation Structure Regulation for High-Performance Aqueous Zinc-Ion Batteries.

Wang Jianxin J, Zhang Han H, Chen Tiancheng T, Jiang Mengdie M et al.

Aqueous zinc-ion batteries (AZIBs) are hailed as promising candidates for next-generation energy storage systems owing to their intrinsic safety, low cost and environmental compatibility. However, their practical deployment is severely hindered by notorious dendrite growth and side reactions, which degrade the plating/stripping reversibility and cycling life. Inspired by the molecular-bridge strategies extensively implemented for interface construction in perovskite solar cells, pantolactone (PL) is introduced as a multifunctional electrolyte additive to stabilize the Zn anode. PL molecules preferentially adsorb on Zn anode surface, forming a compact molecular-bridge interface layer, which accelerates the desolvation process, regulates interfacial Zn2+ transport and promotes preferential Zn(002) oriented deposition. Moreover, the strong coordination between PL and Zn2+ reconstructs the Zn2+ solvation sheath, decreasing the water activity and inhibiting side reactions. Consequently, Zn||Zn symmetric cells deliver an exceptional cycle lifespan exceeding 3400 h, Zn||NH4V4O10 full cells maintain a high discharge capacity of 236.5 mAh g-1 after 1000 cycles at 5 A g-1, with a capacity retention of 94.1%. This work offers a new paradigm of molecular-bridge interfacial engineering coupling solvation structure regulation for developing high-performance AZIBs.

PMID 43053505
阅读全文 →
PubMedMolecular medicine (Cambridge, Mass.)2026-11-19

ER stress and structural changes induced by rare WFS1 variant identified in autosomal dominant form of WFS1-related disorder.

Borecka Silvia S, Zahradnikova Alexandra A, Varga Lukas L, Stanik Juraj J et al.

WFS1‑related disorders encompass a broad phenotypic spectrum ranging from classical autosomal-recessive Wolfram syndrome to autosomal-dominant Wolfram‑like disorders. Dominant variants may disrupt endoplasmic reticulum (ER) homeostasis, calcium handling, and ER-mitochondria communication. Here, we report a Slovak male patient with a complex multisystem Wolfram‑like phenotype and identify a rare heterozygous in‑frame deletion in WFS1 (c.2608_2619del, p.870_873del). We aimed to determine its pathogenic potential through structural modelling and functional assays. The genetic aetiology was investigated by Sanger sequencing, WGS and MLPA. Structural consequences of the deletion were analysed using AlphaFold3 modelling of wild‑type and mutant wolframin, followed by hydrogen‑bond quantification in ChimeraX. Functional studies were performed in HeLa cells expressing wild‑type WFS1, the rare p.870_873del variant, and two pathogenic controls (p.E809K, p.P724L). ER morphology was assessed by confocal microscopy. ER stress activation was quantified using ERSE‑luciferase reporter assays, XBP1 splicing analysis, and qPCR of UPR‑related genes. Mitochondrial fusion dynamics were measured using the photoconvertible mito‑KikGR1 system. The patient presented with early‑onset insulin‑dependent diabetes mellitus, bilateral cataracts, sensorineural hearing loss, autism spectrum disorder, paroxysmal events, and additional systemic comorbidities. Genetic analysis identified a de novo in‑frame deletion affecting four amino acid residues. Structural modelling showed that the deleted region contributes to a C‑terminal hydrogen‑bonding network, and its loss resulted in a significant reduction of stabilizing interactions. Although ER morphology remained preserved, cells expressing the p.870_873del variant displayed markedly reduced mitochondrial fusion, comparable to both pathogenic controls, indicating impaired ER-mitochondria crosstalk. Functional assays further demonstrated pronounced ER stress, evidenced by significantly increased ERSE‑luciferase activity, increased XBP1 splicing, upregulation of DDIT3 (CHOP), and mild induction of HSPA5 (BiP), consistent with activation of the unfolded protein response. We identified a rare likely pathogenic p.870_873del WFS1 variant associated with an autosomal-dominant WFS1‑related disorder and a multisystem Wolfram‑like phenotype. Combined structural and functional evidence indicates that this variant disrupts protein stability, activates ER stress, and impairs ER-mitochondria communication, supporting its potential pathogenic role.

PMID 43052710
阅读全文 →
PubMedNature communications2026-11-19

Orbital coupling effect enables low-chloride concentration electrolyte for four-electron redox in aqueous zinc | |iodine batteries.

Wang Shuai S, Wang Haoran H, So Mei Yi MY, Han Jing J et al.

The I-/I0/I+ redox chemistry is hindered by the inherent instability of the electrophilic I+, which undergoes hydrolysis in aqueous media or is rapidly consumed by comproportionation with triiodide ions. Here, we design a copper single-atom embedded nitrogen-doped carbon host that synergistically combines d-p orbital hybridization and local low-concentration chloride ions to stabilize the I+. The atomic Cu-Nx sites interact moderately with iodine species through Cu d- and I p-orbital hybridization, which enhances iodine species adsorption, accelerates redox kinetics, and increases the hydrolysis energy barrier of I+. Simultaneously, the Cu-Nx sites promote a localized I-Cl microenvironment through electrostatic interaction, enabling efficient I0/I+ conversion even in a low-concentration Cl- ion electrolyte. As a result, the assembled zinc | |iodine battery exhibits a distinct four-electron dual-voltage plateau, achieving a high capacity of ~408 mAh g-1 at 1 A g-1. Even at a high specific current of 10 A g-1, the cell exhibits a high initial capacity of ~251 mAh g-1 and maintains a capacity retention of 70% with a low decay rate of 0.0062‰ per cycle over 50,000 cycles. This work provides a rational design method for coupling single-atom catalysis with localized ion confinement to realize high-voltage and long-life iodine conversion chemistry.

PMID 43052287
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多insulin